Table 4.
Follow‐up systemic therapy in Japanese versus non‐Japanese patients
| Japanese | Non‐Japanese | |
|---|---|---|
| n = 36† | n = 157† | |
| Number of regimen, n (%) | ||
| Any | 27 (75) | 82 (52) |
| 1 | 7 (19) | 46 (29) |
| 2 | 11 (31) | 18 (11) |
| 3 | 4 (11) | 13 (8) |
| 4 | 4 (11) | 4 (3) |
| 5 | 0 | 1 (1) |
| 6 | 1 (3) | 0 |
| Type of medication, n (%) | ||
| Everolimus | 16 (44) | 35 (22) |
| Sunitinib | 9 (25) | 34 (22) |
| Sorafenib | 9 (25) | 9 (6) |
| Axitinib | 7 (19) | 5 (3) |
| Temsirolimus | 6 (17) | 8 (5) |
| Interferon‐α | 4 (11) | 4 (3) |
| Pazopanib | 3 (8) | 17 (11) |
†The number of patients who discontinued study treatment.